论文部分内容阅读
目的探讨白血病患者骨髓细胞RbAp46基因的表达水平。方法建立实时定量RTPCR方法,利用SYBRGreenⅠ染料检测140例急性白血病(AL)、13例慢性粒细胞白血病(CML)慢性期和7例CML急变期患者以及32例非白血病患者骨髓细胞RbAp46基因的表达水平。结果初诊与复发AL患者骨髓中RbAp46基因表达水平的M估计值分别为178.23和213.65,明显高于完全缓解组和对照组(分别为85.89和88.08);CML慢性期组M估计值为58.27,与对照组比较差异无统计学意义(P>0.05),而CML急变期组M估计值为173.24,明显高于CML慢性期组和对照组。98例初诊AL中除M3、M4亚型M估计值(62.63,130.67)与对照组相比差异无统计学意义外,余均明显高于对照组。初诊AL中RbAp46基因表达水平与bcr/abl、PMLRARα、mdr1基因的表达无相关性,但与WT1基因的表达水平呈正相关,与AML1/ETO融合基因表达呈负相关。结论RbAp46在AL初诊、复发及CML急变期患者骨髓细胞中高表达,可能参与白血病的发生。
Objective To investigate the expression of RbAp46 gene in leukemia patients. Methods Real-time quantitative RTPCR was used to detect the expression of RbAp46 gene in 140 cases of acute leukemia (AL), 13 chronic myeloid leukemia (CML) chronic phase and 7 cases of CML blast crisis as well as 32 cases of non-leukemia patients by SYBR GreenⅠ dye . Results The estimated M values of RbAp46 gene expression in newly diagnosed and relapsed AL patients were 178.23 and 213.65, respectively, which were significantly higher than that of the complete remission and control groups (85.89 and 88.08 respectively). The estimated M of CML chronic phase group was 58.27, There was no significant difference in the control group (P> 0.05), while the estimated value of M in the CML blast crisis group was 173.24, which was significantly higher than that in the CML chronic phase group and the control group. 98 cases of newly diagnosed AL in addition to M3, M4 subtype M estimates (62.63,130.67) compared with the control group, no significant difference, the remaining were significantly higher than the control group. The expression of RbAp46 in newly diagnosed AL was not related to the expression of bcr / abl, PMLRARα and mdr1 genes, but positively correlated with the expression of WT1 gene and negatively correlated with the expression of AML1 / ETO fusion gene. Conclusions RbAp46 is overexpressed in bone marrow cells of newly diagnosed, recurrent and CML patients, which may be involved in the development of leukemia.